CORD-19:e847d433e7424152a9846673209cb73027415ecd / 337709-337943 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T3122","span":{"begin":0,"end":234},"obj":"Sentence"},{"id":"T82871","span":{"begin":0,"end":234},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Of 152 p on dual NA therapy since at least 12 months, the majority receive zidovudine-lamivudine (30.3%) followed by lamivudine-stavudine (27%), zidovudine-didanosine (21.7%), didanosine-stavudine (13.8%), lamivudine-tenofovir (5.9%)."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T412","span":{"begin":0,"end":234},"obj":"Sentence"}],"text":"Of 152 p on dual NA therapy since at least 12 months, the majority receive zidovudine-lamivudine (30.3%) followed by lamivudine-stavudine (27%), zidovudine-didanosine (21.7%), didanosine-stavudine (13.8%), lamivudine-tenofovir (5.9%)."}